Escitalopram in the treatment of major depressive disorder: Clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation

International Journal of Clinical Practice

Volumn 61, Issue 4, 2007, Pages 702-710

  Llorca, P M ^a   Fernandez, J L ^b  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; VENLAFAXINE;

CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL RESEARCH; CONSTIPATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAJOR DEPRESSION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; REMISSION; REVIEW; SIDE EFFECT; SUSTAINED DRUG RELEASE; SWEATING; THERAPY EFFECT; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; HUMANS; META-ANALYSIS AS TOPIC; MODELS, ECONOMETRIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33947370431     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01335.x     Document Type: Review

References (56)

1. Croom KF, Plosker GL. Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics 2003; 21: 1185-209.
2. Keller MB. The long-term treatment of depression. J Clin Psychiatry 1999; 60 (Suppl. 17): 41-5 (discussion 46-8).
3. Thase ME. Long-term nature of depression. J Clin Psychiatry 1999; 60 (Suppl. 14): 3-9 (discussion 31-5).
4. Berto P, D'Ilario D, Ruffo P et al. Depression: cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ 2000; 3: 3-10.
5. Wang PS, Simon G, Kessler RC. The economic burden of depression and the cost-effectiveness of treatment. Int J Methods Psychiatr Res 2003; 12: 22-33.
6. Wells KB, Stewart A, Hays RD et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989; 262: 914-9.
7. Cates M. Selecting antidepressant therapy for patients with major depression. Am J Pharm Educ 2001; 65: 190-4.
8. Hirschfeld RM, Montgomery SA, Aguglia E et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002; 63: 826-37.
9. Liebermann JA. History of the use of antidepressants in primary care. Prim Care Companion J Clin Psychiatry 2003; 5 (Suppl. 7): 6-10.
10. Mann JJ. The medical management of depression. N Engl J Med 2005; 353: 1819-34.
11. Burke WJ. Selective versus multi-transmitter antidepressants: are two mechanisms better than one? J Clin Psychiatry 2004; 65 (Suppl. 4): 37-45.
12. Jain R. Single-action versus dual-action antidepressants. Prim Care Companion J Clin Psychiatry 2004; 6 (Suppl. 1): 7-11.
13. Murdoch D, Keam SJ. Escitalopram: a review of its use in the management of major depressive disorder. Drugs 2005; 65: 2379-404.
14. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18: 911-32.
15. Einarson TR, Arikian SR, Casciano J, Doyle JJ. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 1999; 21: 296-308.
16. Stahl SM, Entsuah R, Rudolph RL. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 2002; 52: 1166-74.
17. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234-41.
18. Brunello N, Mendlewicz J, Kasper S et al. The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. Eur Neuropsychopharmacol 2002; 12: 461-75.
19. Doyle JJ, Casciano J, Arikian S et al. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001; 4: 16-31.
20. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122-31.
21. Henry JA, Rivas CA. Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment. Pharmacoeconomics 1997; 11: 419-43.
22. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7: 191-5.
23. Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50: 345-50.
24. Sanchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 2006; 99: 91-5.
25. 123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. Psychopharmacology (Berl) 2006; 188: 263-72.
26. Lancon C, Verpillat P, Annemans L et al. Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram. Int J Psychiatry Clin Pract 2007 (in press).
27. Olver JS, Burrows GD, Norman TR. The treatment of depression with different formulations of venlafaxine: a comparative analysis. Hum Psychopharmacol 2004; 19: 9-16.
28. Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs 2001; 15: 643-69.
29. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57-64.
30. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65: 1190-6.
31. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-9.
32. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
33. Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000; 57: 503-9.
34. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005; 23: 155-67.
35. Montgomery SA, Hendersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; 21: 297-309.
36. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
37. Hunt SM, McKenna SP. The QLDS: a scale for the measurement of quality of life in depression. Health Policy 1992; 22: 307-19.
38. Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2004; 2: 20.
39. Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385-401.
40. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29: 321-6.
41. Croom KF, Plosker GL. Spotlight on the pharmacoeconomics of escitalopram in depression. CNS Drugs 2004; 18: 469-73.
42. Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005; 27: 111-24.
43. Francois C, Sintonen H, Toumi M. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact. J Med Econ 2002; 5: 91-107.
44. Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003; 4: 12-9.
45. Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004; 20: 869-78.
46. Kulp W, von der Schulenburg JM, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ 2005; 6: 317-21.
47. Thase ME, Entsuah AR, Ahmed S, Sloan DM. Meta-analysis of randomized controlled trials comparing venlafaxine XR and SSRIs: the evidence revisited. In: American Psychiatric Association Annual Meeting. Atlanta, GA, USA; 2005.
48. Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005; 21: 631-42.
49. Lecrubier Y, Bourin M, Moon CA et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997; 95: 485-93.
50. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211-7.
51. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999; 56: 171-81.
52. Wade A, Michael Lemming O, Bang Hedegaard K. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95-102.
53. Eckert L, Lancon C. Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. BMC Psychiatry 2006; 6: 30.
54. Vis PM, van Baardewijk M, Einarson TR. Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: a meta-analysis of randomized clinical trials. Ann Pharmacother 2005; 39: 1798-807.
55. Jonas J, Bose A, Alexopoulos G et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Poster presented at the 45th Annual Meeting of the American College of Neuropsychopharmacology. Hollywood, FL, USA, 3-7 December 2006.
56. Frank L, Revicki DA, Sorensen SV, Shih YC. The economics of selective serotonin reuptake inhibitors in depression: a critical review. CNS Drugs 2001; 15: 59-83.